Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 10:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo plus standard therapy Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Osteopathic Manipulative Medicine in Pregnancy: Physiologic and Clinical Effects

NCT00426244
View directory record Official record
Conditions
Low Back Pain, Pregnancy
Interventions
Osteopathic Manipulative Treatment, Placebo Ultrasound
Other
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Sep 28, 2026, 10:11 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study

NCT04552704
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm
Interventions
CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc, Placebo Administration
Biological · Drug
Lead sponsor
Tianhong Li
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 28, 2026, 10:11 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

NCT04560998
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Peripheral Arterial Disease
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
88
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 28, 2026, 10:11 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

NCT04752332
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Abemaciclib, Standard Adjuvant ET, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Glendale, Arizona • Los Angeles, California • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 28, 2026, 10:11 AM EDT
Withdrawn Phase 3 Interventional

Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)

NCT05061771
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
nomacopan (rVA576), Placebo
Drug · Other
Lead sponsor
AKARI Therapeutics
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Los Angeles, California • Skokie, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 28, 2026, 10:11 AM EDT
Recruiting Phase 1 Interventional

Pharmacologic Augmentation of TMS for Depression With D-serine

NCT06876129
View directory record Official record
Conditions
Depression
Interventions
TMS, D-serine, Placebo
Device · Drug · Other
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 28, 2026, 10:11 AM EDT
Terminated Phase 3 Interventional Results available

Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy

NCT01151137
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dronedarone, Placebo (for Dronedarone)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
3,236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Sep 28, 2026, 10:11 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

NCT03246529
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years to 78 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Gainesville, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 28, 2026, 10:11 AM EDT
Completed Phase 1Phase 2 Interventional

Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection

NCT05010577
View directory record Official record
Conditions
Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis
Interventions
BX004-A, Placebo
Drug
Lead sponsor
BiomX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 28, 2026, 10:11 AM EDT
Completed Phase 2 Interventional Results available

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

NCT05055128
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
X842, X842 Dummy, Lansoprazole, Lansoprazole Dummy
Drug
Lead sponsor
Cinclus Pharma Holding AB
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 28, 2026, 10:11 AM EDT
Completed Phase 2 Interventional Results available

Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs

NCT00201123
View directory record Official record
Conditions
Tuberculosis, AIDS-related Complex
Interventions
Aerosol Interferon-Gamma, Subcutaneous interferon-gamma, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 28, 2026, 10:11 AM EDT
Completed Phase 3 Interventional Results available

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT02677896
View directory record Official record
Conditions
Metastatic Hormone Sensitive Prostate Cancer
Interventions
Enzalutamide, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
34
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 28, 2026, 10:11 AM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

NCT03163446
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions
CF-301, Placebo
Biological · Drug
Lead sponsor
ContraFect
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Sep 28, 2026, 10:11 AM EDT
Recruiting Phase 3 Interventional

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

NCT07383441
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Clostridium butyricum CBM 588 Probiotic Strain, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Nivolumab and Recombinant Human Hyaluronidase, Pembrolizumab, Placebo Administration
Drug · Procedure · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
41
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Rogers, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 28, 2026, 10:11 AM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

NCT05624749
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
ianalumab, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
15
States / cities
Anniston, Alabama • La Palma, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 28, 2026, 10:11 AM EDT
Terminated Phase 3 Interventional Results available

Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment

NCT03052517
View directory record Official record
Conditions
Asthma
Interventions
QAW039 150 mg, QAW039 450 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
2,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
46
States / cities
Birmingham, Alabama • Encinitas, California • Newport Beach, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Sep 28, 2026, 10:11 AM EDT
Completed Not applicable Interventional Results available

Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

NCT01117454
View directory record Official record
Conditions
Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions
Flecainide Acetate, Placebo, Beta blocker
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
5 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 28, 2026, 10:11 AM EDT
Recruiting Phase 3 Interventional

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

NCT07177339
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Depemokimab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 75 Years
Enrollment
1,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
42
States / cities
Newport Beach, California • Lakewood, Colorado • Brandon, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 28, 2026, 10:11 AM EDT
Completed Phase 2 Interventional

Evaluation of the Utility of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma

NCT00456677
View directory record Official record
Conditions
Asthma
Interventions
minocycline, Placebos
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 28, 2026, 10:11 AM EDT
Terminated Phase 2 Interventional

Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy

NCT02542215
View directory record Official record
Conditions
Oral Mucositis
Interventions
Cobiprostone, Placebo, Standard Care - Chemotherapy, Standard Care - Radiation
Drug · Radiation
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
76
States / cities
Birmingham, Alabama • Peoria, Arizona • Yuma, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2019 · Synced Sep 28, 2026, 10:11 AM EDT
Not listed Not applicable Interventional

Safety and Efficacy Study of Deep Transcranial Magnetic Stimulation in Bipolar Depression

NCT01566591
View directory record Official record
Conditions
Bipolar Depression
Interventions
Deep TMS Treatment, Sham Treatment
Device
Lead sponsor
Brainsway
Industry
Eligibility
22 Years to 68 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
9
States / cities
Juno Beach, Florida • Palm Beach, Florida • Royal Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Sep 28, 2026, 10:11 AM EDT
Withdrawn Phase 1 Interventional

Sirolimus in COVID-19 Phase 1

NCT04371640
View directory record Official record
Conditions
SARS-CoV-2, Covid-19
Interventions
Sirolimus 1 MG/ML, Placebo
Drug
Lead sponsor
Walter K. Kraft
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 28, 2026, 10:11 AM EDT
Completed Phase 3 Interventional

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

NCT04368559
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
Interventions
Rezafungin for Injection, Posaconazole, Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Intravenous Placebo, Oral Placebo
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 28, 2026, 10:11 AM EDT
Completed Not applicable Interventional

Preventative Osteopathic Manipulative Treatment (OMT) and the Nursing Home Patient

NCT01000142
View directory record Official record
Conditions
General Health Status
Interventions
Osteopathic Manipulative Treatment, Light Touch
Procedure
Lead sponsor
A.T. Still University of Health Sciences
Other
Eligibility
65 Years to 100 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Kirksville, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 28, 2026, 10:11 AM EDT